Deepti Radia
About
Deepti Radia is a scholar working on Genetics, Rheumatology and Immunology.
According to data from OpenAlex, Deepti Radia has authored 87 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Genetics, 41 papers in Rheumatology and 40 papers in Immunology. Recurrent topics in Deepti Radia's work include Eosinophilic Disorders and Syndromes (37 papers), Mast cells and histamine (36 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers). Deepti Radia is often cited by papers focused on Eosinophilic Disorders and Syndromes (37 papers), Mast cells and histamine (36 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers). Deepti Radia collaborates with scholars based in United Kingdom, United States and Germany. Deepti Radia's co-authors include Claire Harrison, Ruben A. Mesa, Ayalew Tefferi, Beverley J. Hunt, Donal P. McLornan, Björn Andréasson, Tiziano Barbui, Mark W. Drummond, Alessandro Rambaldi and Alessandro M. Vannucchi and has published in prestigious journals such as Nature Medicine, Blood and Cancer.
In The Last Decade
Deepti Radia
81 papers receiving 1.6k citations
Peers
Deepti Radia
Steven Fruchtman United States
Robin Filshie Australia
Leroy R. Lard Netherlands
Lisy Wang United States
Judit Demeter Hungary
Valérie Coiteux France
Philippe Mineur Belgium
Andrew Duncombe United Kingdom
Jorge Vela‐Ojeda Mexico
Masamitsu Karasawa Japan
Citations per year, relative to Deepti Radia Deepti Radia (= 1×)
peers
Steven Fruchtman
Countries citing papers authored by Deepti Radia
Since
Specialization
Citations
This map shows the geographic impact of Deepti Radia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepti Radia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepti Radia more than expected).
Fields of papers citing papers by Deepti Radia
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Deepti Radia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepti Radia. The network helps show where Deepti Radia may publish in the future.
Co-authorship network of co-authors of Deepti Radia
This figure shows the co-authorship network connecting the top 25 collaborators of Deepti Radia. A scholar is included among the top collaborators of Deepti Radia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepti Radia. Deepti Radia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lübke, Johannes, Nicole Naumann, Roland Repp, et al.. (2025). Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis. British Journal of Haematology. 207(4). 1388–1396.
2.
Duminuco, Andrea, Natalia Curto‐García, Priya Sriskandarajah, et al.. (2025). QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms. Leukemia. 39(10). 2384–2390.
3.
Reiter, Andreas, Jason Gotlib, Iván Álvarez‐Twöse, et al.. (2025). Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study. Leukemia Research. 157. 107919–107919.
4.
Duminuco, Andrea, Joshua Au Yeung, Natalia Curto‐García, et al.. (2024). Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms. HemaSphere. 8(8). e143–e143.
5.
Harrington, Patrick, Richard Dillon, Deepti Radia, et al.. (2022). Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype. British Journal of Haematology. 198(6). 1011–1015.
6.
Alimam, Samah, Richard Dillon, Michael A. Simpson, et al.. (2021). Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Advances. 5(4). 1059–1068.
7.
DeAngelo, Daniel J., Deepti Radia, Tracy I. George, et al.. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine. 27(12). 2183–2191.
8.
Harrington, Patrick, Hugues de Lavallade, Katie J. Doores, et al.. (2021). Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 35(12). 3573–3577.
9.
Harrington, Patrick, Claire Harrison, Richard Dillon, et al.. (2021). Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). British Journal of Haematology. 193(4). 692–696.
10.
Moonim, Mufaddal, Deepti Radia, Natalia Curto‐García, et al.. (2021). Clinicopathological characterisation of myeloproliferative neoplasm‐unclassifiable (MPN‐U): a retrospective analysis from a large UK tertiary referral centre. British Journal of Haematology. 193(4). 792–797.
11.
Naumann, Nicole, Johannes Lübke, William Shomali, et al.. (2021). Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations. British Journal of Haematology. 194(2). 344–354.
12.
George, Tracy I., Karen Moser, Andreas Reiter, et al.. (2021). Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. Blood. 138(Supplement 1). 2565–2565.
13.
Curto‐García, Natalia, Andrew J. Doyle, Karen Breen, et al.. (2020). Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK. British Journal of Haematology. 189(3). e79–e81.
14.
Alimam, Samah, Claire Harrison, Richard Dillon, et al.. (2020). Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. British Journal of Haematology. 193(1). 150–154.
15.
Maurer, Marcus, Vito Sabato, Katrin Hartmann, et al.. (2020). Results from PIONEER: A randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM). University of Southern Denmark Research Portal (University of Southern Denmark).
16.
Doyle, Andrew J., Karen Breen, Donal P. McLornan, et al.. (2019). Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism. Blood. 134(Supplement_1). 4183–4183.
17.
Radia, Deepti, et al.. (2019). Diagnosis and management of primary immune thrombocytopenia in adults. British Journal of Hospital Medicine. 80(4). C54–C57.
18.
Desterro, Joana, Donal P. McLornan, Natalia Curto‐García, et al.. (2019). Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience. British Journal of Haematology. 186(4). 561–564.
19.
Gotlib, Jason, Deepti Radia, Daniel J. DeAngelo, et al.. (2018). Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood. 132(Supplement 1). 351–351.
20.
Gleixner, Karoline V., Barbara Peter, K. Blatt, et al.. (2013). Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 98(9). 1450–1457.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Steven Fruchtman Breakdown of academic impact, for papers by Robin Filshie Breakdown of academic impact, for papers by Leroy R. Lard Breakdown of academic impact, for papers by Lisy Wang Breakdown of academic impact, for papers by Judit Demeter Breakdown of academic impact, for papers by Valérie Coiteux Breakdown of academic impact, for papers by Philippe Mineur Breakdown of academic impact, for papers by Andrew Duncombe Breakdown of academic impact, for papers by Jorge Vela‐Ojeda Breakdown of academic impact, for papers by Masamitsu Karasawa